Using this compound along with murine- and human-derived organoid models and patient-derived xenografts (PDX), we demonstrate that eIF4E phosphorylation is necessary for bladder cancer progression and is a requirement for the therapeutic response to eFT508, which represents a potentially new therapeutic vulnerability in bladder cancer that can extend survival. This evidence concerns the gene EIF4E and urinary bladder cancer.